embalaje : 100mg
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Curcumin is an inhibitor of tyrosinase with IC50 value of 47uM [1].
Curcumin is a natural compound with potency of anticancer. It is currently under clinical investigation for cancer chemoprevention. There is a variety of biochemical mechanisms of this anticancer function. The targets of Curcumin are involved in signaling pathways include transcription factors, growth factors,
inflammatory cytokines, receptors, and enzymes. Phase I trials have tested the toxicity and tolerability of Curcumin and found that Curcumin has no toxicities at doses up to 12 g/day. However, the bioavailability of Curcumin is quite poor. It is about ~1% after oral administration in phase I/II clinical trials and this hinders Curcumin‘s use in the clinic [2].
It is also reported that Curcumin reduces the generation of amloid beta (Aβ 40 and Aβ42) in SH-SY5Y neuroblastoma cells. It also down-regulates the expression of PS1 and GSK-3β in cells. All these cause the inhibition of Aβ formation and make Curcumin to be a potent therapeutic agent in AD [3].
References:[1] Sachiko Shirota, Kouji Miyazaki, Ritsuo Aiyama, Minoru Ichioka and Teruo Yokokura. Tyrosinase inhibitors from crude drugs. Biol. Pharm. Bull. 1994, 17 (2): 266-269.[2] Wungki Park, A.R.M Ruhul Amin, Zhuo Georgia Chen, and Dong M. Shin. New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013, 6(5): 387–400.[3] Zhang Xiong, Zhang Hongmei, SiLu, LiYu. Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer’s disease. Pharmacological Reports. 2013, 63: 1101-1108.
Cell lines
B16-R melanoma cells resistant to doxorubicin
Reaction Conditions
1 ~ 200 μM curcumin for 24, 36 or 48 h incubation
Applications
Curcumin was found to be cytotoxic in vitro for B16-R melanoma cells resistant to doxorubicin either cultivated as monolayers (1 ~ 100 μM) or grown in three-dimensional cultures (1 ~ 200 μM). The cytotoxic effect observed in the 2 culture types was related to the induction of programmed cell death.
Animal models
Female B6D2F1 mice (6 ~ 8 weeks old) challenged subcutaneously with B16-R melanoma cells
Dosage form
25 mg/kg
Once daily by intraperitoneal injection
The combination treatment consisting of curcumin and soluble B16-R proteins resulted in substantial inhibition of growth of B16-R melanoma, whereas each treatment by itself showed little effect. Moreover, animals receiving the combination therapy exhibited an enhancement of their humoral anti-soluble B16-R protein immune response and a significant increase in their median survival time. Therefore, curcumin may provide a valuable tool for the development of a therapeutic combination against the melanoma.
Note
The technical data provided above is for reference only.
References:
1. Odot J, Albert P, Carlier A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. International Journal of Cancer, 2004, 111(3): 381-387.